Scopus Biopharma Inc Quick Ratio (SCPS) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Scopus Biopharma Inc   (SCPS)

Scopus Biopharma Inc 's Quick Ratio

SCPS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 0.03 below Scopus Biopharma Inc average.

Within Major Pharmaceutical Preparations industry 597 other companies have achieved higher Quick Ratio than Scopus Biopharma Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 3168 to 5341.

Explain Quick Ratio?
How much Cash & cash equivalents SCPS´s has?
What are SCPS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SCPS Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change 104.83 % 81.25 % 78.75 % 164.59 % -38.91 %
Y / Y Cash & cash equivalent Change -68.69 % -64.74 % -98.43 % -91.44 % -81.53 %
Quick Ratio MRQ 0.03 0.15 0.02 0.05 0.22
SCPS's Total Ranking # 5341 # 3168 # 5248 # 4411 # 3740
Seq. Current Liabilities Change 18.13 % 24.94 % 25.93 % 10.21 % 4.53 %
Seq. Cash & cash equivalent Change -74.16 % 1025.01 % -59.92 % -73.12 % -70.91 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 598
Healthcare Sector # 1182
Overall Market # 5341


Quick Ratio Statistics
High Average Low
1.9 0.61 0.02
(Dec 31 2021)   (Dec 31 2022)




Financial Statements
Scopus Biopharma Inc 's Current Liabilities $ 11 Millions Visit SCPS's Balance sheet
Scopus Biopharma Inc 's Cash & cash equivalent $ 0 Millions Visit SCPS's Balance sheet
Source of SCPS's Sales Visit SCPS's Sales by Geography


Cumulative Scopus Biopharma Inc 's Quick Ratio

SCPS's Quick Ratio for the trailling 12 Months

SCPS Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 99.14 % 37.96 % 21.37 % 6.66 % -18.92 %
Y / Y Cash & cash equivalent TTM Growth -86.84 % -86.28 % -78.67 % -33.01 % -0.38 %
Quick Ratio TTM 0.07 0.11 0.23 0.65 0.99
Total Ranking TTM # 3854 # 2811 # 4205 # 0 # 4092
Seq. Current Liabilities TTM Growth 20.07 % 17.48 % 15.94 % 21.77 % -16.82 %
Seq. Cash & cash equivalent TTM Growth -26.54 % -46.23 % -58.41 % -19.88 % -23.4 %

Quick ratio ranking by company, industry and sector >> Back to SCPS Financial Strength Comparisons >> Go to Compare SCPS Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2023 to $11.00 millions, cumulative Quick Ratio decreased to 0.07 below the Scopus Biopharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 597 other companies have achieved higher Quick Ratio than Scopus Biopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 2811 to 3854.

Explain Quick Ratio?
How much Cash & cash equivalents SCPS´s has?
What are SCPS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 598
Healthcare Sector # 1182
Within the Market # 3854


trailing twelve months Quick Ratio Statistics
High Average Low
1.9 0.61 0.02
(Dec 31 2021)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
China Pharma Holdings Inc  0.09 $ 0.902  Millions$ 10.547  Millions
Innovation1 Biotech Inc   0.08 $ 0.210  Millions$ 2.494  Millions
Nabriva Therapeutics Plc  0.08 $ 2.182  Millions$ 26.203  Millions
Baudax Bio Inc   0.07 $ 1.416  Millions$ 20.457  Millions
Accustem Sciences Inc   0.07 $ 0.121  Millions$ 1.765  Millions
One World Products Inc   0.06 $ 0.226  Millions$ 3.661  Millions
Skye Bioscience Inc   0.06 $ 0.558  Millions$ 9.817  Millions
Cdt Equity Inc   0.05 $ 0.278  Millions$ 5.310  Millions
Celularity Inc   0.05 $ 3.084  Millions$ 64.976  Millions
Aeon Biopharma inc   0.05 $ 0.441  Millions$ 9.461  Millions
Dmk Pharmaceuticals Corporation  0.05 $ 0.670  Millions$ 14.675  Millions
Ocean Biomedical Inc   0.04 $ 1.161  Millions$ 27.144  Millions
Athersys Inc  0.04 $ 1.803  Millions$ 42.697  Millions
Altamira Therapeutics Ltd   0.04 $ 0.055  Millions$ 1.423  Millions
Acer Therapeutics Inc   0.04 $ 1.553  Millions$ 43.428  Millions
Northwest Biotherapeutics Inc  0.04 $ 1.424  Millions$ 39.925  Millions
Scopus Biopharma Inc   0.03 $ 0.362  Millions$ 11.002  Millions
Cingulate Inc   0.03 $ 0.350  Millions$ 10.995  Millions
Neptune Wellness Solutions Inc   0.03 $ 1.398  Millions$ 45.026  Millions
Hst Global Inc   0.03 $ 0.002  Millions$ 0.089  Millions
Emmaus Life Sciences Inc   0.02 $ 1.361  Millions$ 61.547  Millions
Zyversa Therapeutics Inc   0.02 $ 0.229  Millions$ 10.485  Millions
Cytodyn inc   0.02 $ 2.541  Millions$ 119.796  Millions
Provectus Biopharmaceuticals Inc   0.02 $ 0.176  Millions$ 8.934  Millions
Cnbx Pharmaceuticals Inc   0.02 $ 0.044  Millions$ 2.348  Millions
Procaps Group S a   0.02 $ 11.538  Millions$ 640.217  Millions
Bioxytran Inc   0.02 $ 0.045  Millions$ 2.763  Millions
Avenir Wellness Solutions Inc   0.02 $ 0.175  Millions$ 11.579  Millions
Orgenesis Inc   0.01 $ 0.180  Millions$ 12.711  Millions
Axim Biotechnologies Inc   0.01 $ 0.107  Millions$ 8.366  Millions

Date modified: 2026-08-29T17:42:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.